29 results on '"Hankui Lu"'
Search Results
2. 2016 Chinese expert consensus and guidelines for the diagnosis and treatment of papillary thyroid microcarcinoma
- Author
-
Ming Gao, Minghua Ge, Qinghai Ji, Ruochuan Cheng, Hankui Lu, Haixia Guan, Li Gao, Zhuming Guo, Tao Huang, Xiaoming Huang, Xiaoming Li, Yansong Lin, Qinjiang Liu, Xin Ni, Yi Pan, Jianwu Qin, Zhongyan Shan, Hui Sun, Xudong Wang, Zhengang Xu, Yang Yu, Daiwei Zhao, Naisong Zhang, Sheng Zhang, Ying Zheng, Jingqiang Zhu, Dapeng Li, Xiangqian Zheng, Chinese Association of Thyroid Oncology, (CATO), and Chinese Anti-Cancer Association
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Published
- 2017
- Full Text
- View/download PDF
3. Clinical Evaluation of the Immune Colloidal Gold Method for Rapid Qualitative and Quantitative Measurement of Thyroid-Stimulating Hormone as an Assay for Hypothyroidism
- Author
-
Yunchao Gao, Yumin Jiang, Tingting Wang, Hankui Lu, Jing Yan, Jianying Gu, Meifang Ruan, and Shiwei Sheng
- Subjects
Adult ,Male ,endocrine system ,medicine.medical_specialty ,China ,Comparative Effectiveness Research ,genetic structures ,endocrine system diseases ,Pharmacology toxicology ,Thyrotropin ,030209 endocrinology & metabolism ,Gold Colloid ,Sensitivity and Specificity ,03 medical and health sciences ,0302 clinical medicine ,Immune system ,Thyroid-stimulating hormone ,Hypothyroidism ,Internal medicine ,medicine ,Humans ,Pharmacology (medical) ,business.industry ,Clinical Laboratory Techniques ,Reproducibility of Results ,General Medicine ,Middle Aged ,body regions ,Endocrinology ,Colloidal gold ,030220 oncology & carcinogenesis ,Female ,business ,Clinical evaluation ,hormones, hormone substitutes, and hormone antagonists ,Hormone - Abstract
The immune colloidal gold (ICG) method of measuring thyroid-stimulating hormone (TSH) is a rapid and easy-to-perform test, allowing off-site measurements. This study compared the clinical utility of the first ICG-based qualitative and quantitative TSH test methods in China with the third-generation serum TSH assay used worldwide.Fingertip and venous blood was collected within 30 min from 283 patients initially suspected of hypothyroidism. TSH was measured in fingertip blood using ICG-based qualitative quantitative tests. Serum TSH in venous blood was tested using the third-generation serum TSH assay. Correlations between systems were tested by kappa or Spearman correlation coefficients.Compared with the third-generation serum TSH assay, the ICG-qualitative TSH test kit had a kappa coefficient of 0.86, a sensitivity of 85.00%, and a specificity of 99.38% in screening for hypothyroidism. The percentages of false negatives and false positives among all subjects were 6.38% and 0.35% respectively; the total consistency rate of the two methods was 93.26%. When compared with the third-generation serum TSH assay, the ICG-quantitative TSH analysis system had a Spearman correlation coefficient of 0.91, a sensitivity of 88.43%, and a specificity of 98.77%. The percentages of false negatives and false positives among all subjects were 4.95% and 0.71%, respectively; the total consistency rate of the two methods was 94.35%.Both ICG-based assays are easier and faster to perform than the third-generation, laboratory-based serum TSH assay method. The ICG-based methods showed acceptable performance in the simplified screening for hypothyroidism.ClinicalTrials.gov identifier, NCT01921452.Merck Serono Co., Ltd.
- Published
- 2016
4. Short-Term Side Effects after Radioiodine Treatment in Patients with Differentiated Thyroid Cancer
- Author
-
Liyan Lu, Fengling Shan, Wen-Bin Li, and Hankui Lu
- Subjects
Adult ,Male ,medicine.medical_specialty ,Adolescent ,Drug-Related Side Effects and Adverse Reactions ,Article Subject ,lcsh:Medicine ,Pain ,030209 endocrinology & metabolism ,General Biochemistry, Genetics and Molecular Biology ,Salivary Glands ,Iodine Radioisotopes ,03 medical and health sciences ,0302 clinical medicine ,Oral administration ,Internal medicine ,Vertigo ,medicine ,Humans ,Vocal cord paralysis ,Thyroid Neoplasms ,Neoplasm Metastasis ,Adverse effect ,Thyroid cancer ,Lymph node ,Aged ,General Immunology and Microbiology ,biology ,Salivary gland ,business.industry ,Thyroid ,lcsh:R ,General Medicine ,Middle Aged ,medicine.disease ,biology.organism_classification ,Surgery ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Clinical Study ,Female ,Radiopharmaceuticals ,business - Abstract
Objectives. I-131 therapy for differentiated thyroid cancer (DTC) could induce adverse effects. The purpose of this study was to report and analyze symptoms after I-131 treatment within the hospitalization and present relevant medical intervention.Methods. I-131 doses ranging from 3.7 to 9.25 GBq (100–250 mCi) were administrated for thyroid remnant ablation or treating DTC metastases. 117 patients with DTC for I-131 therapy were monitored through the video and intercommunicating with standardized questionnaire at different time points after I-131 oral administration. Adverse effects were recorded and relevant clinical factors were analyzed.Results. Among all the 117 patients, 55 cases complained of neck’s pain or swelling and 79 cases presented with gastrointestinal symptoms. Pain or swelling of salivary gland occurred in 15 patients, headache and vertigo in 10, insomnia in 9, vocal cord paralysis in 6, fatigue or general malaise in 6, and foreign body sensation in 5. Body numbness and urinary symptoms were observed in only 1 case, respectively. Those side effects were related with sex, pre-I-131 treatment TSH levels, frequency of I-131 therapy, and lymph node metastases.Conclusions. Short-term side effects after I-131 therapy for DTC patients varied individually; severe symptoms were not uncommon but generally did not need emergent medical intervention.
- Published
- 2016
- Full Text
- View/download PDF
5. I111n-Labeled Cystine-Knot Peptides Based on the Agouti-Related Protein for Targeting Tumor Angiogenesis
- Author
-
Lei Jiang, Jennifer R. Cochran, Gang Ren, Zhen Cheng, Adam P. Silverman, Hongguang Liu, Richard H. Kimura, Hankui Lu, and Zheng Miao
- Subjects
Biodistribution ,Peptidomimetic ,Health, Toxicology and Mutagenesis ,Integrin ,Peptide ,Biology ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,In vivo ,Genetics ,DOTA ,Receptor ,Molecular Biology ,030304 developmental biology ,chemistry.chemical_classification ,0303 health sciences ,Cystine knot ,General Medicine ,Molecular biology ,chemistry ,Biochemistry ,030220 oncology & carcinogenesis ,biology.protein ,Molecular Medicine ,Biotechnology - Abstract
Agouti-related protein (AgRP) is a 4-kDa cystine-knot peptide of human origin with four disulfide bonds and four solvent-exposed loops. The cell adhesion receptor integrinαvβ3is an important tumor angiogenesis factor that determines the invasiveness and metastatic ability of many malignant tumors. AgRP mutants have been engineered to bind to integrinαvβ3with high affinity and specificity using directed evolution. Here, AgRP mutants 7C and 6E were radiolabeled with111In and evaluated forin vivotargeting of tumor integrinαvβ3receptors. AgRP peptides were conjugated to the metal chelator 1, 4, 7, 10-tetra-azacyclododecane- N,N′,N″,N‴-tetraacetic acid (DOTA) and radiolabeled with111In. The stability of the radiopeptides111In-DOTA-AgRP-7C and111In-DOTA-AgRP-6E was tested in phosphate-buffered saline (PBS) and mouse serum, respectively. Cell uptake assays of the radiolabeled peptides were performed in U87MG cell lines. Biodistribution studies were performed to evaluate thein vivoperformance of the two resulting probes using mice bearing integrin-expressing U87MG xenograft tumors. Both AgRP peptides were easily labeled with111In in high yield and radiochemical purity (>99%). The two probes exhibited high stability in phosphate-buffered saline and mouse serum. Compared with111In-DOTA-AgRP-6E,111In-DOTA-AgRP-7C showed increased U87MG tumor uptake and longer tumor retention (5.74±1.60and1.29±0.02%ID/g at 0.5 and 24 h, resp.), which was consistent with measurements of cell uptake. Moreover, the tumor uptake of111In-DOTA-AgRP-7C was specifically inhibited by coinjection with an excess of the integrin-binding peptidomimetic c(RGDyK). Thus,111In-DOTA-AgRP-7C is a promising probe for targeting integrinαvβ3positive tumors in living subjects.
- Published
- 2012
6. Tumor Markers in Thyroid Carcinoma With Pulmonary Metastases After Thyroidectomy
- Author
-
Ruisen Zhu, Yunchao Gao, Hankui Lu, and Zhibin Yuan
- Subjects
Oncology ,medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,Biochemistry (medical) ,Clinical Biochemistry ,Thyroidectomy ,Cancer ,Gastrointestinal mucosa ,medicine.disease ,Gastroenterology ,Serology ,Thyroid carcinoma ,Internal medicine ,medicine ,Thyroglobulin ,In patient ,business ,Tumor marker - Abstract
Background The present study investigated several tumor markers in patients receiving multiple radioiodine treatments after thyroidectomy for differentiated thyroid carcinoma (DTC). Methods Serological tests for tumor markers (Tg, CFEA, CA125, CA19-9, CA72-4, and Cyfra 21-1) were performed in 57 patients with pulmonary metastases (subjects) and 76 patients without distant metastases (controls). Results Serum thyroglobulin was much higher in the subjects than in the controls (median, 595.0 versus 5.4 μg/L, P 0.05). CA72-4 was positive in 20.3% with more positive cases in those having received higher doses (cutoff dose 25.9 GBq, 36.8% versus 13.7%, P =0.003). Conclusion These tumor markers are not likely progression-related and are not recommended for the follow up of DTC patients unless other malignancies are indicated. The high sensitivity of CA72-4 may be related to radiation damage to the gastrointestinal mucosa.
- Published
- 2009
7. Incremental Value of 131I SPECT/CT in the Management of Patients with Differentiated Thyroid Carcinoma
- Author
-
Ruisen Zhu, Hankui Lu, Yan Shen, Libo Chen, Quan-Yong Luo, Yongli Yu, and Zhibin Yuan
- Subjects
Adult ,Male ,medicine.medical_specialty ,Planar Imaging ,Adolescent ,Scintigraphy ,Sensitivity and Specificity ,Iodine Radioisotopes ,Thyroid carcinoma ,Young Adult ,Text mining ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Thyroid Neoplasms ,Child ,Prospective cohort study ,Thyroid tumors ,Aged ,Tomography, Emission-Computed, Single-Photon ,medicine.diagnostic_test ,business.industry ,Thyroid ,Reproducibility of Results ,Middle Aged ,medicine.anatomical_structure ,Subtraction Technique ,Female ,Tomography ,Radiology ,Radiopharmaceuticals ,Tomography, X-Ray Computed ,Nuclear medicine ,business - Abstract
131I whole-body scintigraphy (WBS) is a highly sensitive method for the detection of differentiated thyroid tumors and metastases. However, a lack of anatomic landmarks and the physiologic accumulation of the tracer complicate interpretation of the images. This prospective study was designed to evaluate the incremental value of 131I SPECT/CT over planar WBS in the management of patients with differentiated thyroid carcinoma (DTC). Methods: Planar imaging was performed on 66 consecutive DTC patients who were considered to have locally advanced or metastatic disease after total or nearly total thyroidectomy. SPECT/CT was added for patients whose planar findings were inconclusive. The planar images were interpreted by 2 experienced nuclear medicine physicians. Interpretation of the SPECT/CT images was a consensus opinion of one of the nuclear medicine physicians and an experienced radiologist. Fusion images were considered to improve image interpretation when they better localized sites of increased 131I uptake. The final diagnosis was verified by pathologic findings, other imaging modalities, and clinical follow-up. Both site-based and patient-based analyses were performed, and the impact of SPECT/CT results on therapeutic strategy was assessed. Results: A total of 232 foci were observed by 131I WBS, including 33.2% of foci localized in the thyroid bed, 62.1% due to malignant lesions, and 4.7% caused by nonthyroidal physiologic or benign uptake or a contaminant. Overall, 37 SPECT/CT studies were performed on 23 patients, whose planar images showed 81 inconclusive lesions. Precise localization and characterization of 131I-avid foci were achieved through 131I SPECT/CT in 69 (85.2%) and 67 (82.7%) of the 81 foci, respectively. Fusion images were considered to be of benefit in 17 (73.9%) of 23 patients. The therapeutic strategy was changed in 8 (47.1%) of 17 patients. Uncommon metastatic lesions were found in 9 (13.6%) of 66 patients with regard to SPECT/CT fusion images. Conclusion: Fusion of SPECT and CT images was of incremental value over WBS in increasing diagnostic accuracy, reducing pitfalls, and modifying therapeutic strategies in 73.9% of DTC patients. As SPECT/CT techniques emerge, 131I SPECT/CT may demonstrate higher value than WBS in the management of DTC.
- Published
- 2008
8. Preparation and bioevaluation of 99mTc-HYNIC-annexin B1 as a novel radioligand for apoptosis imaging
- Author
-
Shuhan Sun, Ruisen Zhu, Yi Zhang, Zhi-yong Zhang, Quan-Yong Luo, Fang Wang, and Hankui Lu
- Subjects
Blood Platelets ,Cancer Research ,Biodistribution ,Fas Ligand Protein ,Annexins ,Clinical Biochemistry ,Pharmaceutical Science ,Apoptosis ,Phosphatidylserines ,Thymus Gland ,Annexin A5 affinity assay ,Biology ,Kidney ,Ligands ,Dexamethasone ,Mice ,Annexin ,Radioligand ,medicine ,Animals ,Humans ,Platelet activation ,Pharmacology ,Biochemistry (medical) ,Biological activity ,Organotechnetium Compounds ,Cell Biology ,Molecular biology ,medicine.anatomical_structure ,Liver - Abstract
Annexin B1, a novel Ca2+-dependent PS-binding protein, has been shown to have a high affinity for PS exposed on the surface of apoptotic cells. To develop and bioevaluate an annexin B1 based PS-targeting radiotracer, annexin B1 was radiolabeled with (99m)Tc using HYNIC as a bifunctional chelator. Binding assays with activated platelets and apoptotic SP2/0 cells were carried out to evaluate the in vitro biological activity of (99m)Tc-HYNIC-annexin B1. Biodistribution of this radioligand was studied in normal mice. Dexamethasone-induced murine thymus apoptosis and fas-mediated murine liver apoptosis models were used to investigate the ability of radiolabeled annexin B1 to detect apoptosis in vivo. The labeling procedure yielded a compound with up to 98% radiochemical purity and good in vitro stability. The in vitro binding assays indicated that (99m)Tc-HYNIC-annexin B1 retain its PS-binding activity. Biodistribution of the compound in mice showed that (99m)Tc-HYNIC-annexin B1 is rapidly cleared from the blood and predominantly accumulates in the kidney. The marked increase in dexamethasone-treated murine thymus uptake and fas-mediated murine liver uptake correlated with histologic evidence of apoptosis. These data suggested that (99m)Tc-HYNIC-annexin B1 retain its in vitro and in vivo biological activities. This radiotracer may therefore be useful as a novel radioligand for the noninvasive detecting of PS externalization associated with apoptosis.
- Published
- 2008
9. Effect of freeze–thaw cycles on serum measurements of AFP, CEA, CA125 and CA19‐9
- Author
-
Y.‐D. Yang, Hankui Lu, Yunchao Gao, and Zhi-bin Yuan
- Subjects
Adult ,Male ,Pathology ,medicine.medical_specialty ,CA-19-9 Antigen ,endocrine system diseases ,Clinical Biochemistry ,Specimen Handling ,Andrology ,Carcinoembryonic antigen ,Neoplasms ,Freezing ,Biomarkers, Tumor ,medicine ,Humans ,Statistical analysis ,Aged ,Single cycle ,Sample handling ,biology ,medicine.diagnostic_test ,Chemistry ,Reproducibility of Results ,Repeated measures design ,General Medicine ,Middle Aged ,digestive system diseases ,Carcinoembryonic Antigen ,CA-125 Antigen ,Immunoassay ,biology.protein ,Female ,CA19-9 ,alpha-Fetoproteins ,Frozen storage - Abstract
AFP, CEA, CA125 and CA19-9 are commonly used serum tumour markers (TMs) in clinical practice, although their quantification by immunoassay may be influenced by pre-analytical sample handling. Though the effect of repetitive freeze-thaw cycles is generally recognized, it is not clear in detail. The present study measured (CLIA) these TMs in serum samples freshly separated and after each of five freeze-thaw cycles, in which the samples were frozen at -40 degrees C for 10 months at cycle 4 and 2 h at other cycles. Statistical analysis with the General Linear Model for Repeated Measures revealed significant decreases in the measurements of the four TMs, with the least decrease of 6.8 % for CA125 and the most decrease of 18.2 % for CA19-9 after the last cycle, and an overwhelming single cycle decrease of mean 7.7 % at cycle 4 for AFP, CEA and CA125, of 7.5 % and 9.3 % at cycles 4 and 5 for CA19-9. So it seems that measurements of AFP, CEA and CA125 are more readily affected by long-term frozen storage compared with frequent freezing-thawing, while CA19-9 is relatively unstable under both conditions.
- Published
- 2007
10. 99mTc-pertechnetate uptake in hepatoma cells due to tissue-specific human sodium iodide symporter gene expression
- Author
-
Annette Altman, Libo Chen, Walter Mier, Ruisen Zhu, Hankui Lu, and Uwe Haberkorn
- Subjects
Sodium-iodide symporter ,Cancer Research ,Reporter gene ,Symporters ,Metabolic Clearance Rate ,Gene Expression ,Transfection ,Biology ,Molecular biology ,In vitro ,Rats ,Viral vector ,Liver Neoplasms, Experimental ,Organ Specificity ,In vivo ,Cell Line, Tumor ,Gene expression ,Animals ,Molecular Medicine ,Tissue Distribution ,Radiology, Nuclear Medicine and imaging ,Radiopharmaceuticals ,Radionuclide Imaging ,Enhancer ,Sodium Pertechnetate Tc 99m - Abstract
The sodium iodide symporter (NIS) gene could be used as an ideal reporter gene as well as a promising therapeutic gene. 99m Tc-pertechnetate has proven to be more advantageous than 131 I-iodide with respect to image quality, procedure and radiation dose in examination of thyroid uptake and scintigraphy. Herein, we investigated the feasibility of monitoring human sodium iodide symporter (hNIS) gene expression with 99m Tc-pertechnetate in hepatoma cells (MH3924A) following tissue-specific expression. Methods MH3924A cells were stably transfected with the recombinant retroviral vector, in which hNIS cDNA was driven by murine albumin enhancer/promoter (mAlb) and coupled to hygromycin resistance gene using an internal ribosomal entry site. Functional NIS expression in hepatoma cells was confirmed by an 125 I − uptake assay. The dynamic uptake and efflux of 99m Tc-pertechnetate was determined both in vitro and in vivo. Results The 99m Tc-pertechnetate was up to 254-fold higher in stably transfected MH3924A cells than in wild-type cells. However, the in vitro efflux of 99m Tc-pertechnetate out of recombinant cells was rapid with a half-life of less than 2 min. Further, the in vivo studies yielded clear images and quantitative data of mAlbhNIS-infected tumor xenografts using 99m Tc-pertechnetate and γ camera. Conclusion The current study demonstrates enhanced 99m Tc-pertechnetate uptake in hepatoma cells in vitro and in vivo following tissue-specific gene transfer using a recombinant retrovirus with the albumin enhancer/promoter and the hNIS gene. It is feasible to monitor hNIS gene expression noninvasively and quantitatively using conventional γ camera and 99m Tc-pertechnetate.
- Published
- 2006
11. FDG-anorectic parathyroid carcinoma with FDG-avid bone metastasis on PET/CT images
- Author
-
Yunchao Gao, Hankui Lu, and Mei Li
- Subjects
Male ,medicine.medical_specialty ,Parathyroid hormone ,Bone Neoplasms ,Scintigraphy ,Metastasis ,Lesion ,Fluorodeoxyglucose F18 ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,PET-CT ,medicine.diagnostic_test ,business.industry ,Bone metastasis ,General Medicine ,Middle Aged ,medicine.disease ,Parathyroid Neoplasms ,Parathyroid carcinoma ,Positron emission tomography ,Positron-Emission Tomography ,Radiology ,medicine.symptom ,business ,Tomography, X-Ray Computed - Abstract
A 53-year-old man complained of aggravated left hip pain of more than 2 months. Whole-body (18)F-FDG PET/CT revealed only 1 hypermetabolic lesion in the left ilium. Histopathologic examination of the lesion suggested metastatic disease. Blood tests documented mildly elevated blood calcium and parathyroid hormone. Subsequent neck ultrasonography, contrast-enhanced CT, and dual-phase scintigraphy with (99m)Tc-MIBI showed a right parathyroid tumor, which was confirmed to be a parathyroid carcinoma postoperatively. We report a case of parathyroid carcinoma rarely encountered with a FDG-negative primary but a FDG-positive metastasis on PET/CT images.
- Published
- 2013
12. Brain metastasis from follicular thyroid carcinoma: treatment with sorafenib
- Author
-
Maomei Ruan, Ruisen Zhu, Libo Chen, Hankui Lu, Quan-Yong Luo, Yongli Yu, and Yan Shen
- Subjects
Oncology ,Sorafenib ,Niacinamide ,medicine.medical_specialty ,Lung Neoplasms ,Pyridines ,Endocrinology, Diabetes and Metabolism ,medicine.medical_treatment ,Antineoplastic Agents ,Thyroid carcinoma ,Lesion ,Iodine Radioisotopes ,Endocrinology ,Internal medicine ,Adenocarcinoma, Follicular ,medicine ,Humans ,Molecular Targeted Therapy ,Thyroid Neoplasms ,Protein Kinase Inhibitors ,business.industry ,Brain Neoplasms ,Phenylurea Compounds ,Therapeutic effect ,Benzenesulfonates ,Thyroidectomy ,Middle Aged ,medicine.disease ,Treatment Outcome ,Response Evaluation Criteria in Solid Tumors ,Adenocarcinoma ,Female ,medicine.symptom ,business ,Brain metastasis ,medicine.drug - Abstract
Sorafenib has shown promise in the treatment of patients with advanced or metastatic thyroid carcinoma. However, its therapeutic effect has not been assessed in patients with brain metastases from follicular thyroid carcinoma (FTC). Here, we report a patient in whom this treatment was employed with a relatively favorable response.A 56-year-old woman had a thyroidectomy 8 years previously for FTC. She subsequently developed lung metastases, for which she received seven courses of radioiodine ((131)I) therapy. She developed right hemiplegia and other symptoms and was found to have a ≈ 5-cm lesion in the left parietal lobe. Radiosurgery with a total dose of 28 Gy (7 Gy/day, for 4 days) to treat her brain metastatic lesion was ineffective, and she was referred to us. We treated her with sorafenib, 200 mg orally, on a twice-daily basis. The effect of this intervention was assessed clinically and radiographically using Response Evaluation Criteria in Solid Tumors (RECIST).Symptoms and signs improved dramatically and continuously after initiation of sorafenib treatment. Partial response (PR) in the brain metastasis and stable disease (SD) in lung metastatic lesions were verified by consecutive imaging findings for more than one year. Despite alopecia, other treatment-related adverse events did not occur.Targeted therapy such as with sorafenib could be an effective alternative therapeutic strategy in the treatment of progressive brain metastasis from differentiated thyroid carcinoma (DTC) when surgery, external beam radiation, and (131)I are not suitable or give poor outcomes. A paradigm of sustained low dose of sorafenib (200 mg,twice a day) may be well-tolerated without compromising maintenance of the therapeutic effect.
- Published
- 2012
13. Imaging proliferation in human leukemia-tumor bearing mice with (18)F-FLT: Comparison with (18)F-FDG PET
- Author
-
Liyan, Lu, Lei, Jiang, Haixia, Guan, Yunchao, Gao, and Hankui, Lu
- Subjects
Male ,Mice, Inbred BALB C ,Mice, Nude ,Reproducibility of Results ,Image Enhancement ,Sensitivity and Specificity ,Dideoxynucleosides ,Mice ,Fluorodeoxyglucose F18 ,Cell Line, Tumor ,Leukemia, Myelogenous, Chronic, BCR-ABL Positive ,Positron-Emission Tomography ,Animals ,Humans ,Neoplasm Invasiveness ,Radiopharmaceuticals ,K562 Cells - Abstract
Leukemia threatens human life due to its uncontrolled proliferative malignancy. 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) has been suggested as a new positron emission tomography (PET) tracer for imaging tumor proliferation. The aim of the study was to investigate the usefulness of (18)F-FLT PET for imaging human leukemia-tumor bearing mice, compared with fluorine-18-fluorodesoxyglucose ((18)F-FDG PET). In vitro the experiments of (18)F-FLT and (18)F-FDG uptake were performed in K562 cell lines at various time points and radioactive tracer uptake was measured in a gamma counter. (18)F-FLT and (18)F-FDG PET imaging were performed both in the same mouse when eight tumor-bearing mice models of human chronic myeloid leukemia were established successfully by injecting K562 cells. Regions of interest were drawn over the tumor, the crossed normal tissue was regarded as background and the ratio of tumor to non-tumor counts (T/NT) in tissues was calculated. A higher uptake of (18)F-FLT (15min, 5.73±0.05%; 30min, 5.90±0.06%; 60min, 6.16±0.19%; 120min, 6.32±0.08%) than that of (18)F-FDG (15min, 1.05±0.10%; 30min, 1.11±0.14%; 60min, 1.14±0.37%; 120 min, 1.36±0.25%) was observed in K562 cells in the tracer uptake experiment. Ratios of T/NT of (18)F-FLT PET (0.5h, 5.39±0.42; 1h, 4.88±0.43; 2h, 3.81±0.38) were higher than those of (18)F-FDG PET/CT (0.5h, 0.34±0.12; 1h, 0.21±0.06; 2h, 0.13±0.05) after injection. Both uptake and T/NT differences of (18)F-FLT versus (18)F-FDG were significant (P0.05). In conclusion, (18)F-FLT and (18)F-FDG quantitative and semi-quantitative uptake measurements resulting from cell lines and PET imaging respectively suggested a promising potential of (18)F-FLT for metabolic imaging of human chronic myeloid leukemia.
- Published
- 2012
14. 111In-labeled cystine-knot peptides based on the Agouti-related protein for targeting tumor angiogenesis
- Author
-
Lei, Jiang, Zheng, Miao, Richard H, Kimura, Adam P, Silverman, Gang, Ren, Hongguang, Liu, Hankui, Lu, Jennifer R, Cochran, and Zhen, Cheng
- Subjects
Neovascularization, Pathologic ,Brain Neoplasms ,digestive, oral, and skin physiology ,Indium Radioisotopes ,Molecular Sequence Data ,Transplantation, Heterologous ,Mice, Nude ,Cystine-Knot Miniproteins ,Heterocyclic Compounds, 1-Ring ,Mice ,Cell Line, Tumor ,Animals ,Humans ,Agouti-Related Protein ,Female ,Tissue Distribution ,Amino Acid Sequence ,Glioblastoma ,Radionuclide Imaging ,Research Article - Abstract
Agouti-related protein (AgRP) is a 4-kDa cystine-knot peptide of human origin with four disulfide bonds and four solvent-exposed loops. The cell adhesion receptor integrin α(v)β(3) is an important tumor angiogenesis factor that determines the invasiveness and metastatic ability of many malignant tumors. AgRP mutants have been engineered to bind to integrin α(v)β(3) with high affinity and specificity using directed evolution. Here, AgRP mutants 7C and 6E were radiolabeled with (111)In and evaluated for in vivo targeting of tumor integrin α(v)β(3) receptors. AgRP peptides were conjugated to the metal chelator 1, 4, 7, 10-tetra-azacyclododecane- N, N', N″, N'''-tetraacetic acid (DOTA) and radiolabeled with (111)In. The stability of the radiopeptides (111)In-DOTA-AgRP-7C and (111)In-DOTA-AgRP-6E was tested in phosphate-buffered saline (PBS) and mouse serum, respectively. Cell uptake assays of the radiolabeled peptides were performed in U87MG cell lines. Biodistribution studies were performed to evaluate the in vivo performance of the two resulting probes using mice bearing integrin-expressing U87MG xenograft tumors. Both AgRP peptides were easily labeled with (111)In in high yield and radiochemical purity (99%). The two probes exhibited high stability in phosphate-buffered saline and mouse serum. Compared with (111)In-DOTA-AgRP-6E, (111)In-DOTA-AgRP-7C showed increased U87MG tumor uptake and longer tumor retention (5.74 ± 1.60 and 1.29 ± 0.02%ID/g at 0.5 and 24 h, resp.), which was consistent with measurements of cell uptake. Moreover, the tumor uptake of (111)In-DOTA-AgRP-7C was specifically inhibited by coinjection with an excess of the integrin-binding peptidomimetic c(RGDyK). Thus, (111)In-DOTA-AgRP-7C is a promising probe for targeting integrin α(v)β(3) positive tumors in living subjects.
- Published
- 2011
15. A first described chest wall metastasis from colon cancer demonstrated with (18)F-FDG PET/CT
- Author
-
Lei, Jiang, Yunchao, Gao, Shiwei, Sheng, Min, Xu, Liyan, Lu, and Hankui, Lu
- Subjects
Fluorodeoxyglucose F18 ,Positron-Emission Tomography ,Colonic Neoplasms ,Humans ,Thoracic Wall ,Tomography, X-Ray Computed - Abstract
It is well known that, haematogenous colon cancer metastases are most commonly found in the liver, less likely in the lungs through the paravertebral venous system and rarely in other organs. Sporadic clinical cases of colon cancer metastases to the abdominal wall, the thyroid or the adrenal glands have been reported. Here, we present an uncommon case of chest wall metastasis from colon cancer demonstrated with 2-fluoro [fluorine-18]-2-deoxy-D-glucose ((18)F-FDG) positron emission tomography/computed tomography (PET/CT). A 52 years old female patient was examined after she felt a swelling mass above her left breast. Tumor makers, such as serum cancer embryonic antigen (CEA) 146.22kU/L (normal range:0.00~37.0kU/L) and CA19-9 (258.16μg/L (normal range:0.00~10.0μg/L) and neuron-specific enolase (NSE) 78.2 (normal range: 0.00~17.00) were abnormally high. Chest CT revealed the soft tissue density mass on the left anterior chest wall with invasion of left 4th rib, and CT-guided biopsy showed a poorly differentiated adenocarcinoma of unkown origin. The patient was then referred for the (18)F-FDG-PET scan which was performed one hour after the intravenous injection of 370MBq of (18)F-FDG (Discovery Camera, VCT, GE, USA) and showed in addition to the chest mass, abnormal (18)F-FDG accumulation in both lungs, left supraclavicular and peritoneal lymph nodes. Furthermore, high (18)F-FDG uptake was detected in the sigmoid. Pathology findings from colonoscopy confirmed that this was a sigmoid colon adenocarcinoma. So far, chest wall metastasis from colon cancer as an initial finding has not been reported. Usually, an initial chest wall mass is hardly suspected to be a colon cancer metastasis. Abnormal serum tumor markers such as CEA and CA19-9 supported the diagnosis of a gastrointestinal adenocarcinoma. In our case, we found high serum NSE and normal findings of bowel wall on the CT scan, thus without the positive (18)F-FDG findings, one would probably consider as first diagnosis: chest wall metastasis from lung cancer, or a neuroendocrine tumor. The unusual finding in this case was that on the CT images there was no obvious local density of the intestine, no bowel wall thickening, or suspicious nodular lesions. Segmental (18)F-FDG accumulation seen in the sigmoid colon had early maximum standardized uptake value (SUV(max)) 7.3 and in 1h delayed estimation, 8.1. Colonoscopy showed that the (18)F-FDG-avid area at the colon was circular and thickened. "Hot" lesions found in both lungs, the supraclavicular and retroperitoneal lymph nodes by (18)F-FDG PET/CT scan were considered to be most probably metastases from colon adenocarcinoma. In conclusion, PET as a rather simple procedure and less dependent on bowel preparation diagnosed the primary colon cancer, its metastases and specifically a first described chest wall metastasis, while CT alone did not show the primary tumor.
- Published
- 2011
16. Response to sorafenib at a low dose in patients with radioiodine-refractory pulmonary metastases from papillary thyroid carcinoma
- Author
-
Libo Chen, Yan Shen, Quan-Yong Luo, Hankui Lu, Ruisen Zhu, and Yongli Yu
- Subjects
Sorafenib ,Oncology ,Adult ,Male ,Niacinamide ,medicine.medical_specialty ,China ,Lung Neoplasms ,Pyridines ,Endocrinology, Diabetes and Metabolism ,Antineoplastic Agents ,Gastroenterology ,Thyroid carcinoma ,Iodine Radioisotopes ,Endocrinology ,Refractory ,Internal medicine ,medicine ,Carcinoma ,Humans ,Thyroid Neoplasms ,Treatment Failure ,Adverse effect ,Thyroid cancer ,Aged ,Dose-Response Relationship, Drug ,business.industry ,Phenylurea Compounds ,Benzenesulfonates ,Middle Aged ,medicine.disease ,Carcinoma, Papillary ,Clinical trial ,Treatment Outcome ,Response Evaluation Criteria in Solid Tumors ,Thyroid Cancer, Papillary ,Disease Progression ,Female ,business ,medicine.drug - Abstract
Sorafenib has shown promise in the treatment of patients with advanced or metastatic thyroid carcinoma. However, the optimal dose has not been established and data on Chinese population are not available. We conducted a study to assess the responses to sorafenib at a low dose of 200 mg twice daily in patients with progressive radioiodine-refractory pulmonary metastases from papillary thyroid carcinoma (PTC).Eligible patients received sorafenib 200 mg orally twice daily. Responses were assessed using Response Evaluation Criteria in Solid Tumors and adverse events were assessed periodically. The end points included response rate and progression-free survival.Nine patients with radioiodine-refractory PTC were enrolled in the study and treated for a minimum of 13 weeks. The objective partial response rate was 33%. The stable disease rate was 44%. The mean progression-free survival was 42 weeks (95% confidence interval, 29.5 to 53.9). Two patients showed disease progression, and one of them died at 4 months after beginning of treatment. There was a marked and rapid change in the serum thyroglobulin level after start of treatment, with a mean decrease of 60% within 12 weeks, consistent with radiographic findings. Although the types of toxicities were consistent with other sorafenib trials, their severity was relatively mild. None of the patients discontinued sorafenib or reduced their dose because of treatment-related adverse events.Sorafenib at a dose of 200 mg twice daily has a potential therapeutic effect and is well tolerated in Chinese patients with PTC and radioiodine-refractory pulmonary metastases. Further study is warranted with a larger cohort of patients.
- Published
- 2010
17. Pulmonary fibrosis following radioiodine therapy of pulmonary metastases from differentiated thyroid carcinoma
- Author
-
Yan Shen, Yongli Yu, Quan-Yong Luo, Libo Chen, Ruisen Zhu, and Hankui Lu
- Subjects
Oncology ,medicine.medical_specialty ,Lung Neoplasms ,business.industry ,Endocrinology, Diabetes and Metabolism ,Pulmonary Fibrosis ,Radioiodine therapy ,medicine.disease ,Carcinoma, Papillary ,Thyroid carcinoma ,Iodine Radioisotopes ,Endocrinology ,Text mining ,Internal medicine ,Pulmonary fibrosis ,Carcinoma ,Medicine ,Humans ,Female ,Thyroid Neoplasms ,business ,Child - Published
- 2010
18. FDG PET/CT Showing Erythema Nodosum Associated With Tuberculous Lymphadenitis
- Author
-
Hankui Lu, Xiaohua Chen, and Yunchao Gao
- Subjects
Adult ,Pathology ,medicine.medical_specialty ,Septal panniculitis ,Tuberculin ,Tuberculosis, Lymph Node ,Multimodal Imaging ,Erythema Nodosum ,Fluorodeoxyglucose F18 ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Erythema nodosum ,integumentary system ,medicine.diagnostic_test ,business.industry ,Mediastinum ,General Medicine ,medicine.disease ,Tuberculous lymphadenitis ,medicine.anatomical_structure ,Positron emission tomography ,Positron-Emission Tomography ,Skin biopsy ,Female ,Lymph ,Tomography, X-Ray Computed ,business - Abstract
Erythema nodosum (EN) is histopathologically an acute septal panniculitis of subcutaneous adipose lobule. It can be either idiopathic or secondary to various underlying conditions. A female patient with EN underwent FDG PET/CT to search underlying cause. The images showed enlarged lymph nodes in the mediastinum with moderately elevated FDG uptake and multifocal increased FDG uptake over her lower extremities. The patient's condition was subsequently diagnosed with EN associated with mediastinal tuberculous lymphadenitis based on skin biopsy, tuberculin skin test, and treatment response.
- Published
- 2013
19. Predictive value of osteocalcin in bone metastatic differentiated thyroid carcinoma
- Author
-
Qiong Luo, Yunchao Gao, Xiaohui Wu, Hankui Lu, and Shiwei Sheng
- Subjects
Male ,medicine.medical_specialty ,Clinical Biochemistry ,Osteocalcin ,Bone Neoplasms ,Gastroenterology ,Collagen Type I ,Thyroid carcinoma ,Internal medicine ,Biomarkers, Tumor ,Medicine ,Humans ,Thyroid Neoplasms ,Risk factor ,Neoplasm Metastasis ,Thyroid cancer ,biology ,medicine.diagnostic_test ,business.industry ,Bone metastasis ,Cancer ,General Medicine ,Middle Aged ,medicine.disease ,Alkaline Phosphatase ,Predictive value ,Endocrinology ,Immunoassay ,biology.protein ,Female ,business ,Procollagen - Abstract
Objectives To evaluate the diagnostic value of serum osteocalcin in the detection of bone metastases from differentiated thyroid carcinoma (DTC). Design and methods Serum samples from DTC patients with (DTC BM+, n = 19) or without bone metastases (DTC BM−, n = 19), and matched healthy volunteers (n = 30) were tested for serum osteocalcin with electrochemiluminescent immunoassay. Results Osteocalcin was higher in DTC BM+ than in DTC BM− patients (+ 35.8%, p = 0.002), acting as an independent risk factor for bone metastases (R2 = 0.142, p = 0.039). The sensitivity was 78.9% and the specificity was 63.2% at a cut-off value of 11.2 μg/L. Conclusions Serial measurements of osteocalcin could be useful in the detection of bone metastases from DTC.
- Published
- 2009
20. Comparison of free plasma metanephrines enzyme immunoassay with (131)I-MIBG scan in diagnosis of pheochromocytoma
- Author
-
Ying Ding, Hankui Lu, Yun-chao Gao, Ruisen Zhu, Quan-Yong Luo, and Libo Chen
- Subjects
Adult ,Male ,Pathology ,medicine.medical_specialty ,Urology ,Adrenal Gland Neoplasms ,Electrochemical detection ,Pheochromocytoma ,Normetanephrine ,EIA method ,General Biochemistry, Genetics and Molecular Biology ,Immunoenzyme Techniques ,chemistry.chemical_compound ,Medicine ,Humans ,In patient ,Radionuclide Imaging ,Metanephrine ,Chromatography, High Pressure Liquid ,medicine.diagnostic_test ,business.industry ,General Medicine ,Metanephrines ,Middle Aged ,medicine.disease ,3-Iodobenzylguanidine ,chemistry ,Immunoassay ,Female ,business - Abstract
Measurement of free plasma metanephrines (metanephrine and normetanephrine), usually performed by high-performance liquid chromatography with electrochemical detection (HPLC-ECD), has been recommended as the single biochemical test of choice for the diagnosis of pheochromocytoma. Alternatively, a widely available, simple means to measure these biomarkers with enzyme immunoassay (EIA) needs to be studied. The aim of this study was to investigate the diagnostic efficacy of such a method in comparison with (131)I-metaiodobenzylguanidine (MIBG) whole body scan (WBS) in patients with pheochromocytoma. We enrolled patients undergoing (131)I-MIBG WBS due to clinical findings suggestive of pheochromocytoma (n = 45), and patients with primary hypertension (n = 36). All subjects had blood tests for free plasma metanephrine (MN) and normetanephrine (NM) with a commercially available EIA kit. WBS was positive in 30 pheochromocytoma patients and negative in 15 refuted ones, with 100% accuracy. The sensitivity, specificity and accuracy of MN and NM in combination (either or both positive) were 96.7%, 86.3% and 90.1%, showing comparable diagnostic performance both to (131)I-MIBG WBS (all p0.1), and also to the same markers measured with HPLC-ECD reported in the literature. These results showed that the EIA method may be eligible as an alternative to HPLC-ECD for plasma metanephrine determination in the identification of pheochromocytoma.
- Published
- 2007
21. Mutual interference between serum thyroglobulin and antithyroglobulin antibody in an automated chemiluminescent immunoassay
- Author
-
Yunchao Gao, Hankui Lu, Yongli Yu, and Zhi-bin Yuan
- Subjects
Chromatography ,Chemistry ,medicine.medical_treatment ,Clinical Biochemistry ,Reproducibility of Results ,General Medicine ,Thyroglobulin ,Serum thyroglobulin ,Automation ,Chemiluminescent immunoassay ,Luminescent Measurements ,medicine ,Humans ,Thyroid Neoplasms ,Artifacts ,Antithyroglobulin antibody ,Autoantibodies - Abstract
Objectives: To investigate the analytical interference between serum Tg and TgAb. Design and methods: Tg and TgAb were measured on an automated chemiluminescent immunoassay system in mixed sera from DTC patients and individual samples spiked with exogenous Tg. Results: Tg and TgAb recoveries in mixed patient samples were inversely correlated with expected TgAb or Tg concentrations, respectively. Impaired TgAb recoveries were also found in 50% (10/20) samples with high Tg in the exogenous recovery tests. Conclusions: Mutual but not equal analytical interference between Tg and TgAb is present and concentration-dependent with interpatient variability.
- Published
- 2006
22. The role of radionuclide lymphoscintigraphy in extremity lymphedema
- Author
-
Quan-Yong Luo, Hankui Lu, Jifang Zhu, Libo Chen, Ruisen Zhu, and Zhibin Yuan
- Subjects
Adult ,Male ,medicine.medical_specialty ,Adolescent ,Organotechnetium Compounds ,Sensitivity and Specificity ,hemic and lymphatic diseases ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Radionuclide imaging ,Lymphedema ,Child ,Radionuclide Imaging ,Aged ,Retrospective Studies ,Radionuclide ,business.industry ,Reproducibility of Results ,Dextrans ,General Medicine ,Middle Aged ,medicine.disease ,humanities ,body regions ,Child, Preschool ,Female ,Radiology ,Lymph Nodes ,Radiopharmaceuticals ,Nuclear medicine ,business - Abstract
The characteristics of lymphedema on radionuclide lymphoscintigraphy were studied, and the diagnostic value of radionuclide lymphoscintigraphy in lymphedema was evaluated. In this report radionuclide lymphoscintigraphy was performed in 110 cases of clinically suspected lymphedema. A retrospective study method was used to analyze the imaging results. The typical pattern of lymphedema on radionuclide lymphoscintigraphy was summarized. It was found that the characteristics of lymphedema on radionuclide lymphoscintigraphy were diverse. The most common pattern was increased radiotracer accumulation in the soft tissue and lymphatic webs. Surgery and infection dominated as the causes of lymphedema in this study. It was concluded that radionuclide lymphoscintigraphy is a useful noninvasive method for diagnosing lymphedema. It is easy to operate and provides reliable results.
- Published
- 2006
23. Preparation, in vitro and in vivo evaluation of (99m)Tc-Annexin B1: a novel radioligand for apoptosis imaging
- Author
-
Quan-Yong Luo, Ruisen Zhu, Zhi-yong Zhang, Hankui Lu, Yu-zhi Guo, and Fang Wang
- Subjects
Blood Platelets ,Biodistribution ,Annexins ,Biophysics ,Apoptosis ,Biochemistry ,chemistry.chemical_compound ,Mice ,Drug Stability ,Annexin ,In vivo ,Radioligand ,Animals ,Humans ,Tissue Distribution ,Platelet activation ,Radionuclide Imaging ,Molecular Biology ,Cells, Cultured ,Mice, Inbred BALB C ,Ligand binding assay ,Reproducibility of Results ,Cell Biology ,Phosphatidylserine ,Organotechnetium Compounds ,Molecular biology ,chemistry ,Organ Specificity ,Isotope Labeling ,Immunology ,Radiopharmaceuticals - Abstract
To develop a radiopharmaceutical for apoptosis imaging, Annexin B1, a new Ca 2+ -dependent phosphatidylserine (PS)-binding protein, was directly radiolabeled with 99m Tc. This procedure yields up to 96% of radiochemical purity and higher radiolabeling efficiency. The preparation has been found to be sufficiently stable in vitro. Binding assay with human activated platelets indicated that 99m Tc-Annexin B1 retained its PS binding activity. Biodistribution in mice revealed that 99m Tc-Annexin B1 rapidly cleared from the blood and predominantly accumulated in the kidney. The increase in hepatic uptake in anti-Fas antibody treated mice correlated to histologic evidence of fulminant hepatic apoptosis. These data suggest that 99m Tc-Annexin B1 can be used as a novel radiotracer to detect apoptosis in vivo.
- Published
- 2005
24. Multiple Subdermal Metastases from Papillary Thyroid Cancer
- Author
-
Libo Chen, Yongli Yu, Quan-Yong Luo, Hankui Lu, Ruisen Zhu, and Qiong Luo
- Subjects
Oncology ,medicine.medical_specialty ,Endocrinology ,Text mining ,business.industry ,Endocrinology, Diabetes and Metabolism ,Internal medicine ,Medicine ,business ,medicine.disease ,Papillary thyroid cancer - Published
- 2008
25. Localization of Concomitant Metastases to Kidney and Erector Spinae from Papillary Thyroid Carcinoma Using 131I-SPECT and CT
- Author
-
Qiong Luo, Ruisen Zhu, Quan-Yong Luo, Shiwei Sheng, Hankui Lu, Yongli Yu, and Libo Chen
- Subjects
Oncology ,Thyroid carcinoma ,medicine.medical_specialty ,Kidney ,Endocrinology ,medicine.anatomical_structure ,business.industry ,Endocrinology, Diabetes and Metabolism ,Concomitant ,Internal medicine ,Medicine ,Radiology ,business - Published
- 2008
26. The Role of Radionuclide Bone Scintigraphy in Fibrous Dysplasia of Bone
- Author
-
Zhibin, Yuan, primary, Quanyong, Luo, additional, Libo, Chen, additional, Jun, Zhu, additional, Hankui, Lu, additional, Jifang, Zhu, additional, and Ruisen, Zhu, additional
- Published
- 2004
- Full Text
- View/download PDF
27. Response to Sorafenib at a Low Dose in Patients with Radioiodine-Refractory Pulmonary Metastases from Papillary Thyroid Carcinoma.
- Author
-
Libo Chen, Yan Shen, Quanyong Luo, Yongli Yu, Hankui Lu, and Ruisen Zhu
- Subjects
IODINE isotopes ,PAPILLARY carcinoma ,METASTASIS ,THYROID cancer treatment ,DOSE-response relationship in biochemistry ,DISEASE progression ,THERAPEUTIC equivalency in drugs ,THYROGLOBULIN ,SERUM ,PATIENTS - Abstract
Background:Sorafenib has shown promise in the treatment of patients with advanced or metastatic thyroid carcinoma. However, the optimal dose has not been established and data on Chinese population are not available. We conducted a study to assess the responses to sorafenib at a low dose of 200 mg twice daily in patients with progressive radioiodine-refractory pulmonary metastases from papillary thyroid carcinoma (PTC).Patients and Methods:Eligible patients received sorafenib 200 mg orally twice daily. Responses were assessed using Response Evaluation Criteria in Solid Tumors and adverse events were assessed periodically. The end points included response rate and progression-free survival.Results:Nine patients with radioiodine-refractory PTC were enrolled in the study and treated for a minimum of 13 weeks. The objective partial response rate was 33%. The stable disease rate was 44%. The mean progression-free survival was 42 weeks (95% confidence interval, 29.5 to 53.9). Two patients showed disease progression, and one of them died at 4 months after beginning of treatment. There was a marked and rapid change in the serum thyroglobulin level after start of treatment, with a mean decrease of 60% within 12 weeks, consistent with radiographic findings. Although the types of toxicities were consistent with other sorafenib trials, their severity was relatively mild. None of the patients discontinued sorafenib or reduced their dose because of treatment-related adverse events.Conclusion:Sorafenib at a dose of 200 mg twice daily has a potential therapeutic effect and is well tolerated in Chinese patients with PTC and radioiodine-refractory pulmonary metastases. Further study is warranted with a larger cohort of patients. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
28. Tumor Markers in Thyroid Carcinoma With Pulmonary Metastases After Thyroidectomy.
- Author
-
Yunchao Gao, Hankui Lu, Zhibin Yuan, and Ruisen Zhu
- Subjects
- *
TUMOR markers , *THYROID cancer , *LUNG cancer , *THYROIDECTOMY , *METASTASIS , *CANCER patients , *SEROLOGY ,THERAPEUTIC use of iodine isotopes - Abstract
Background: The present study investigated several tumor markers in patients receiving multiple radioiodine treatments after thyroidectomy for differentiated thyroid carcinoma (DTC).Methods: Serological tests for tumor markers (Tg, CFEA, CA125, CA19-9, CA72-4, and Cyfra 21-1) were performed in 57 patients with pulmonary metastases (subjects) and 76 patients without distant metastases (controls).Results: Serum thyroglobulin was much higher in the subjects than in the controls (median, 595.0 versus 5.4 μg/L, PP>0.05). CA72-4 was positive in 20.3% with more positive cases in those having received higher doses (cutoff dose 25.9 GBq, 36.8% versus 13.7%, P=0.003).Conclusion: These tumor markers are not likely progression-related and are not recommended for the follow up of DTC patients unless other malignancies are indicated. The high sensitivity of CA72-4 may be related to radiation damage to the gastrointestinal mucosa. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
29. Incremental Value of 131I SPECT/CT in the Management of Patients with Differentiated Thyroid Carcinoma.
- Author
-
Libo Chen, Quanyong Luo, Yan Shen, Yongli Yu, Zhibin Yuan, Hankui Lu, and Ruisen Zhu
- Published
- 2008
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.